Catalyst Pharmaceuticals, Inc.

small molecule specialty pharmaceuticals (rare/orphan neuromuscular and CNS disease)

CPRX · Nasdaq · United States

Share price · CPRX

$31.49+5.30 (+20.24%) 3M

no price since 14 Jul 2026

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CPRX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 5 May 2026+6.6%

    Nothing announced by CPRX that day or the session before.

  2. 27 Apr 2026+6.9%
  3. 23 Apr 2026+6.7%

    Nothing announced by CPRX that day or the session before.

  4. 2 Mar 2026+3.5%
  5. 27 Feb 2026-7.2%

    Nothing announced by CPRX that day or the session before.

  6. 25 Feb 2026+2.8%
  7. 13 Feb 2026+3.1%

    Nothing announced by CPRX that day or the session before.

  8. 13 Jan 2026-3.7%

    Nothing announced by CPRX that day or the session before.

Share of unusual movement by asset

For each asset, the share of CPRX's own-move activity since 20 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—0%
Sessions with no dated event—100%

No dated announcements about its assets since 20 Oct 2025.

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Perampanel(Fycompa)
Approved
AMPA receptor (antagonist)Small molecule
Epilepsy
Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
April 2027 (1)
Perampanel · FycompaPhase 2Pediatric Epileptic Syndrome, Partial-onset Seizures
Est. primary completion 2027-04-06 · NCT04015141 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.

Insider transactions

Insider-transaction reporting (SEC Form 4) applies to US-listed SEC filers. No SEC insider-filing record exists for this company's listing.